Sagimet Biosciences Inc. (SGMT) Balance Sheet
As of 2026-06-30 (10-Q), Sagimet Biosciences Inc. (SGMT) reported total assets of $263.4M, total liabilities of $7.3M and shareholders' equity of $256.2M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $165.9M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
SGMTSagimet Biosciences Inc.Follow SGMT — free
—
Price chart with a free account
- Market cap
- 595.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 12 Nov, in 19 days
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|
| Cash and equivalents | 75.1 | 75.8 | 35.0 | 165.9 | |
| Short-term investments | 19.8 | 75.4 | 78.1 | 74.2 | |
| Current assets | 96.6 | 152.8 | 116.4 | 244.0 | |
| Total assets | 96.7 | 160.3 | 116.5 | 263.4 | |
| Current liabilities | 5.7 | 4.5 | 5.1 | 5.4 | |
| Total liabilities | 5.7 | 4.5 | 5.1 | 7.3 | |
| Shareholders' equity | 91.1 | 155.8 | 111.4 | 256.2 |
USD millions · SEC XBRL
Sagimet Biosciences Inc. — questions
- How much cash does Sagimet Biosciences Inc. have?
- $165.9M in cash and cash equivalents as of 2026-06-30.
- What are Sagimet Biosciences Inc.'s total assets?
- $263.4M as of 2026-06-30.
- What is Sagimet Biosciences Inc.'s shareholders' equity?
- $256.2M as of 2026-06-30.
Every figure on this page comes from Sagimet Biosciences Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.